Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal oxytocin before ABA therapy in youth with autism spectrum disorder
IRCT20211004052670N1Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Jan 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of oxytocin in Autism Spectrum Disorder (ASD) (2 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoints: Severity of autism and Strengths and difficulties. Started Jan 2022; status: completed.
02
Drugs
oxytocin
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on IRCT20211004052670N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20211004052670N1.